These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24145312)

  • 1. Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.
    Massa M; Rosti V; Campanelli R; Fois G; Barosi G
    Leukemia; 2014 Feb; 28(2):449-51. PubMed ID: 24145312
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
    Palandri F; Palumbo GA; Elli EM; Polverelli N; Benevolo G; Martino B; Abruzzese E; Tiribelli M; Tieghi A; Latagliata R; Cavazzini F; Bergamaschi M; Binotto G; Crugnola M; Isidori A; Caocci G; Heidel F; Pugliese N; Bosi C; Bartoletti D; Auteri G; Cattaneo D; Scaffidi L; Trawinska MM; Stella R; Ciantia F; Pane F; Cuneo A; Krampera M; Semenzato G; Lemoli RM; Iurlo A; Vianelli N; Cavo M; Breccia M; Bonifacio M
    Blood Cancer J; 2021 Jan; 11(1):4. PubMed ID: 33414394
    [No Abstract]   [Full Text] [Related]  

  • 3. Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.
    Caocci G; Maccioni A; Murgia F; Perra A; Usai M; Piga M; Mascia R; La Nasa G
    Leuk Lymphoma; 2016 May; 57(5):1215-8. PubMed ID: 26308187
    [No Abstract]   [Full Text] [Related]  

  • 4. Ruxolitinib: the first agent approved for myelofibrosis.
    Verstovsek S
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
    Arana Yi C; Tam CS; Verstovsek S
    Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis.
    Maccaferri M; Leonardi G; Marasca R; Colaci E; Paolini A; Soci F; Forghieri F; Potenza L; Narni F; Luppi M
    Leuk Lymphoma; 2014 Sep; 55(9):2207-8. PubMed ID: 24354678
    [No Abstract]   [Full Text] [Related]  

  • 7. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.
    Bjørn ME; Holmström MO; Hasselbalch HC
    Leuk Lymphoma; 2016; 57(1):125-8. PubMed ID: 25936872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?
    Breccia M; Molica M; Colafigli G; Alimena G
    Expert Rev Hematol; 2015 Aug; 8(4):387-9. PubMed ID: 25915176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical management of myelofibrosis with ruxolitinib.
    Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
    Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
    Chen YH; Lee CH; Pei SN
    Leuk Lymphoma; 2015 May; 56(5):1528-9. PubMed ID: 25213182
    [No Abstract]   [Full Text] [Related]  

  • 11. Klebsiella pneumoniae primary liver abscess associated with ruxolitinib.
    Kusano Y; Terui Y; Ueda K; Hatake K
    Ann Hematol; 2016 Sep; 95(9):1561-2. PubMed ID: 27259987
    [No Abstract]   [Full Text] [Related]  

  • 12. [Ruxolitinib prescription in myelofibrosis].
    Lemal R; Robin M; Ravinet A; Cacheux V; Guièze R; Bay JO
    Bull Cancer; 2013 Sep; 100(9):897-902. PubMed ID: 23985569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.
    Iurlo A; Cattaneo D; Boiocchi L; Orofino N; Fermo E; Cortelezzi A; Gianelli U
    Ann Hematol; 2015 Oct; 94(10):1749-51. PubMed ID: 26082334
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term outcome of treatment with ruxolitinib in myelofibrosis.
    Tefferi A; Litzow MR; Pardanani A
    N Engl J Med; 2011 Oct; 365(15):1455-7. PubMed ID: 21995409
    [No Abstract]   [Full Text] [Related]  

  • 15. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
    Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
    Al-Ali HK; Griesshammer M; le Coutre P; Waller CF; Liberati AM; Schafhausen P; Tavares R; Giraldo P; Foltz L; Raanani P; Gupta V; Tannir B; Ronco JP; Ghosh J; Martino B; Vannucchi AM
    Haematologica; 2016 Sep; 101(9):1065-73. PubMed ID: 27247324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib (Jakafi) for myelofibrosis.
    Med Lett Drugs Ther; 2012 Apr; 54(1387):27-8. PubMed ID: 22469651
    [No Abstract]   [Full Text] [Related]  

  • 20. Ruxolitinib for myelofibrosis therapy: current context, pros and cons.
    Pardanani A
    Leukemia; 2012 Jul; 26(7):1449-51. PubMed ID: 22285996
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.